Compare Cronos Group Inc (CRON) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Nike Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Nike Inc trades at $34.76 (market cap $51.60B). The key difference: Nike Inc is far larger — about 43.7× Cronos Group Inc's market cap, and Nike Inc pays a 4.72% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Nike Inc for 155 Days on average.
| CRON | NKE | |
|---|---|---|
Market Cap | $1.18B | $51.60B |
Volume | 968,037 | 43,506,062 |
Sector | Health | Consumer Cyclical |
52-Week High | $3.55 | $69.68 |
52-Week Low | $2.30 | $33.87 |
Typical Hold Time | 22 Days | 155 Days |
Enterprise Value | $387.62M | $54.30B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
Nike (NKE) trades at $34.74, up 0.38% on the day, amid a bearish technical signal and mixed earnings history. The stock shows strong profitability with a 43.07% gross margin and 21.56% ROE, but revenue declined to $46.31B in 2025. Recent news highlights challenges in China and EMEA, while analysts maintain a $36.98 consensus target.
Nike's outlook hinges on executing its turnaround strategy to revive growth. Investment opportunities include brand strength and digital initiatives, but risks involve sluggish demand, margin pressure, and intense competition. The stock's valuation appears reasonable with a P/E of 16.44, yet near-term headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
